How COVID-19 Changes the Game for Biopharma in China

Posted on by

(CC) Jean Scheijen/FreeimagesThe COVID-19 crisis is fundamentally changing how biopharma operate in China. It has put short-term pressure on budgets, reduced treatment of non-COVID-19 patients, and undermined market fundamentals.

The report is available from the McKinsey website.